Show simple item record

FieldValueLanguage
dc.contributor.authorRazavian, Mona
dc.contributor.authorDi Micco, Lucia
dc.contributor.authorPalmer, Suetonia C
dc.contributor.authorCraig, Jonathan C
dc.contributor.authorPerkovic, Vlado
dc.contributor.authorZoungas, Sophia
dc.contributor.authorWebster, Angela C
dc.contributor.authorJardine, Meg J
dc.contributor.authorStrippoli, Giovanni FM
dc.date.accessioned2020-05-12
dc.date.available2020-05-12
dc.date.issued2013-02-28
dc.identifier.citationPalmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, Jardine MJ, Webster AC, Zoungas S, Strippoli GFM. Antiplatelet agents for chronic kidney disease. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD008834.DOI: 10.1002/14651858.CD008834.pub3en
dc.identifier.urihttps://hdl.handle.net/2123/22278
dc.description.abstractTo evaluate the benefits and harms of antiplatelet therapy in patients with any form of kidney disease, including patients with CKD not receiving renal replacement therapy (RRT), patients receiving any form of dialysis, and kidney transplant recipients.en
dc.language.isoenen
dc.rightsOther
dc.titleAntiplatelet agents for chronic kidney diseaseen
dc.typeArticleen
dc.type.pubtypePublisher's versionen
usyd.facultyFaculty of Medicine and Health, Sydney Medical Schoolen


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.